Restoring the eye’s natural cellular “cleanup system” protected retinal neurons in experimental models

Researchers have identified a potential new approach for protecting nerve cells in the eye from the damage caused by glaucoma.

The study suggests that elevated pressure inside the eye may disrupt a natural cellular recycling process called autophagy, preventing retinal cells from efficiently removing damaged mitochondria. Restoring this process protected retinal nerve cells and reduced signs of glaucoma-related degeneration in experimental models.

Glaucoma is a leading cause of irreversible blindness. The disease progressively damages retinal ganglion cells (RGCs)and the nerve fibers that form the optic nerve, eventually resulting in permanent vision loss.

Although lowering intraocular pressure (IOP) remains the most important strategy for slowing glaucoma, some patients continue to experience disease progression despite effective pressure control. The new findings could help explain why and point toward a treatment strategy that protects retinal nerve cells directly.

High eye pressure disrupts mitochondrial health

Mitochondria are essential structures inside cells that produce energy. Like other components of the cell, damaged mitochondria need to be regularly removed and replaced.

The researchers found that chronic elevation of IOP interfered with this process in the retina.

In mouse models of glaucoma, elevated eye pressure was associated with impaired autophagy and mitophagy, the specialized form of autophagy responsible for removing damaged mitochondria.

As a result, abnormal mitochondria accumulated in retinal tissue and the optic nerve. The researchers also observed increased oxidative damage, a form of cellular stress that can contribute to neuronal injury.

Importantly, impaired mitochondrial turnover was detected before significant retinal ganglion-cell loss occurred.

This finding suggests that defective mitochondrial quality control may be an early driver of glaucomatous neurodegeneration rather than simply a consequence of cells dying.

Restoring autophagy protected retinal neurons

The researchers next investigated whether restoring the autophagy process could protect the retina.

They used Torin 2, a small molecule that inhibits mTOR, a cellular pathway that regulates growth and autophagy.

In glaucoma mouse models, treatment with Torin 2 increased autophagy and improved mitochondrial quality. The treatment reduced abnormal mitochondrial accumulation and protected retinal ganglion cells and optic-nerve fibers from degeneration.

The researchers also observed protective effects in cultured human retinal explants, suggesting that the underlying mechanism may be relevant to human retinal tissue.

A potential complement to pressure-lowering treatment

The findings could eventually lead to a new way of thinking about glaucoma treatment.

Current therapies primarily aim to reduce IOP, thereby reducing the pressure that contributes to retinal and optic nerve damage. The new research suggests that another approach may be possible: strengthening the retinal cells themselves by improving their ability to maintain healthy mitochondria.

Such a strategy could potentially complement existing pressure-lowering treatments and might be particularly valuable for patients whose disease continues to progress despite controlled IOP.

However, the researchers emphasize that Torin 2 is not currently an approved treatment for glaucoma. The work remains at the preclinical stage, and additional studies are needed to determine whether safely targeting autophagy or the mTOR pathway can be developed into a treatment for patients.

What this means for patients

The research does not mean that patients should take an mTOR inhibitor or attempt to increase autophagy on their own.

Instead, the study identifies a promising biological pathway that could be targeted by future glaucoma therapies.

The ultimate goal would be to develop treatments that do more than lower eye pressure—treatments that also protect retinal ganglion cells and preserve the connections that carry visual information from the eye to the brain.

For people living with glaucoma, such neuroprotective therapies could one day provide an additional line of defense against progressive vision loss.

About the research

The study, titled “Pharmacological restoration of impaired autophagy in retinal ganglion cells prevents abnormal mitochondrial accumulation and glaucomatous neurodegeneration,” investigated the relationship between elevated IOP, mitochondrial damage, autophagy and retinal neurodegeneration using mouse models of glaucoma and ex vivo human retinal tissue.

The findings provide evidence that impaired mitochondrial turnover is an important component of glaucomatous neurodegeneration and that restoring autophagy may offer a potential avenue for neuroprotective treatment.